（原标题：汉商集团振幅15.56%，上榜营业部合计净卖出3426.44万元） 近半年该股累计上榜龙虎榜7次，上榜次日股价平均涨1.64%，上榜后5日平均跌3.87%。 资金流向方面，今日该股主力资金净流出6489.14万元，其中，特大单净流出3515.08万元，大单资金净流出2974.07万元。近5日主力资金净流入 8486.19万元。 4月30日公司发布的一季报数据显示，一季度公司共实现营业收入2.57亿元，同比下降23.51%，实现净利润276.14万元，同比下降78.21%。（数据 宝） 汉商集团8月4日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | 995.29 | | | 买二 | 东方财富证券股份有限公司拉萨团结路第二证券营业部 | 781.10 | | | 买三 | 财信证券股份有限公司杭州庆春路证券营业部 | 758.73 | | | 买四 | 东方财富证券股份有限公司拉萨东环路第一证券营业部 | 744.70 | | | 买五 ...

Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]

Group 1: New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - ST Kelly (300326) has a tender offer period from July 17, 2025, to August 15, 2025[1] - ST Zitian (300280) has a tender offer period ending on July 21, 2025[1] Group 2: Market Alerts - Xizang Tourism (600749) reported severe abnormal fluctuations on July 31, 2025[1] - Tianlu Convertible Bonds (110060) announced significant market activity on July 30, 2025[1] - ST Suwu (600200) experienced unusual trading patterns on July 30, 2025[1] Group 3: Additional Announcements - Happiness Blue Ocean (300528) issued a notice on July 30, 2025, regarding market conditions[1] - Common Pharmaceutical (300966) provided updates on August 1, 2025, related to stock performance[1] - Dongjie Intelligent (300486) released a statement on August 1, 2025, concerning market volatility[1]

Market Overview - On the first trading day of August, the A-share market experienced overall weakness, with major sectors such as oil and petrochemicals, semiconductors, and non-bank financials adjusting, leading to declines in the three major stock indices [2] - The Shanghai Composite Index closed at 3559.95 points, down 0.37%; the Shenzhen Component Index closed at 10991.32 points, down 0.17%; and the ChiNext Index closed at 2322.63 points, down 0.24% [2] - The total trading volume in the Shanghai and Shenzhen markets was 15,983 billion yuan, a decrease of over 3,300 billion yuan compared to the previous trading day [2] Solar Equipment Sector - The solar equipment sector showed strong performance, with the Shenwan Solar Equipment Index closing up 2.60%, leading all secondary industries [3] - Companies such as Jiejia Weichuang and Shuangliang Energy reached the daily limit [3] - The Ministry of Industry and Information Technology recently issued a special energy-saving inspection task list for the polysilicon industry for 2025, requiring local authorities to implement and report results by September 30 [3] - According to China International Capital Corporation (CICC), this move is aimed at optimizing the supply side of the industry and may lead to the exit of backward production capacity, particularly affecting the upstream polysilicon segment [3] Express Delivery Sector - The express delivery sector also performed actively, with the Shenwan Logistics Index rising by 1.53% [3] - Companies such as YTO Express, Shentong Express, and Yunda Holdings saw increases of over 6%, while other stocks like Debang Logistics also followed suit [3] - On July 29, the State Post Bureau held a meeting with express delivery companies to address issues related to "involution" competition and promote high-quality industry development [4] Innovative Drug Sector - The innovative drug sector remained active, with stocks like Weikang Pharmaceutical hitting a 20% daily limit, and companies such as Anglikang and Guizhou Bailin recording consecutive gains [5] - Recent announcements from companies like Haizike and Huahai Pharmaceutical regarding new drug applications have contributed to the sector's momentum [5] - According to Dongfang Securities, the global innovative drug field is shifting from "Made in China" to "Created in China," with domestic pharmaceutical companies enhancing their international competitiveness [5] Dividend and Resource Sectors - Looking ahead to August, the strategy team at Industrial Securities suggests focusing on dividend sectors and resource industries for investment opportunities [6] - Historical data indicates that the first half of August typically sees fewer companies disclosing semi-annual results, leading to a higher success rate for small-cap stocks [6] - As the month progresses and companies begin to report earnings, larger-cap stocks with earnings certainty are expected to gain more attention, particularly in resource sectors like coal and petrochemicals [6]

证券代码：600774 股票简称：汉商集团 编号：2025-038 汉商集团股份有限公司 股票交易异常波动公告 （一）生产经营情况。 经公司自查，公司目前日常经营情况未发生重大变化。市场环境及行业政 策未发生重大调整，生产成本和销售等情况未出现大幅波动，内部生产经营秩 序正常。 （二）重大事项情况。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 汉商集团股份有限公司（以下简称"公司"）股票交易连续 3 个交易日内（2025 年 7 月 30 日、2025 年 7 月 31 日、2025 年 8 月 1 日）收盘价格涨幅偏离值累计超过 20%。 根据《上海证券交易所交易规则》的相关规定，公司股票交易属于异常波动情况。 截至本公告披露日，公司、控股股东及实际控制人除前期发布的重大资产重组事 项外，不存在其他应披露而未披露的重大事项，包括但不限于重大资产重组、股份发行、 收购、债务重组、业务重组、资产剥离、资产注入、股份回购、股权激励、破产重整、重 大业务合作、引进战略投资者等重大事项。 在公司本次股票交易异常波动 ...

卓尔控股有限公司 关于股票交易异常波动有关情况的回函 汉商集团股份有限公司: 1、截至本函回复之日,除前期已披露的重大资产重组事项外,本公司及一 致行动人未筹划涉及上市公司的其他重大资产重组、股份发行、收购、债务重 组、业务重组、资产剥离、资产注入、股份回购、股权激励、破产重整、重大 业务合作、引进战略投资者等重大事项。 特此回函。 2、在贵公司本次股票交易异常波动期间,本公司及一致行动人不存在买卖 汉商集团股票的情况。 3、在贵公司本次股票交易异常波动期间，本公司及一致行动人未出现其他 可能对上市公司股价产生较大影响的重大事件。 4、在贵公司本次股票交易异常波动期间,本公司及一致行动人不存在其他 应披露而未披露的事项。 贵公司《关于重大事项的询证函》已收悉。本公司作为贵公司控股股东, 经核查,现将有关事项回函如下: ...

汉商集团：公司坚持推进"大健康+大商业"双主业发展战略，主营业务未发生重大变化 金十数据8月1日讯，汉商集团发布异动公告，公司股票交易连续3个交易日内收盘价格涨幅偏离值累计 超过20%，属于异常波动情况。经公司自查，公司目前日常经营情况未发生重大变化。市场环境及行业 政策未发生重大调整，生产成本和销售等情况未出现大幅波动，内部生产经营秩序正常。公司坚持推 进"大健康+大商业"双主业发展战略,主营业务未发生重大变化，基本面亦未发生重大变化。 ...

汉商集团公告，公司股票交易在2025年7月30日、7月31日和8月1日连续3个交易日内收盘价格涨幅累计 超过20%，属于异常波动。经自查和控股股东书面函证核实，公司目前日常经营情况未发生重大变化， 市场环境及行业政策未发生重大调整，生产成本和销售等情况未出现大幅波动，内部生产经营秩序正 常。此外，控股股东及实际控制人不存在买卖公司股票的情况。公司前期公告的重大资产重组事项尚未 取得实质性进展或发生变化。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002940 | 昂利康 | 62.92 | 10.00% | 11.62万 | 7.17亿 | | 601089 | 福元医药 | 26.54 | 9.99% | 10.13万 | 2.68 亿 | | 600774 | 汉商集团 | 12.46 | 9.97% | 31.00万 | 3.72亿 | | 002370 | 亚太药业 | 7.40 | 9.96% | 309.35万 | 22.01亿 | | 002437 | 营衡药业 | 4.04 | 8.89% | 482.38万 | 19.13 Z | | 300966 | 并同药业 | 26.68 | 8.41% | 29.78万 | 8.08亿 | | 688658 | 倪康药业 | 33.79 | 7.82% | 16.60万 | 5.72亿 | | 688091 | 上海谊众 | 77.63 | 7.79% | 12.47万 | 9.36 Z | | 600513 | 联环药业 | 4 ...

格隆汇8月1日｜医药板块持续大涨，众生药业、联环药业、汉商集团等近10只个股涨停，悦康药业涨逾 12%，维康药业涨逾9%。 ...